In children with bronchiolitis, what is the effectiveness of commonly used pharmacological treatments?

**METHODS**

Data sources: Medline (January 1980 to November 2002), Cochrane Central Register of Controlled Trials, reference lists, and technical experts.

Study selection and assessment: single or double blinded randomised controlled trials (RCTs) published in English that evaluated pharmacological treatments for bronchiolitis in >10 children.

Outcomes: death, short and long term morbidity, and use of health services.

**MAIN RESULTS**

44 RCTs of commonly used interventions met the selection criteria. Study quality was rated as excellent in 7 RCTs, good in 20 RCTs, fair in 8 RCTs, and poor in 9 RCTs.

Inhaled bronchodilators, either alone or in combination with inhaled or oral corticosteroids, were compared with placebo or usual care in 15 RCTs, and with each other in 7 RCTs. Inhaled bronchodilators did not reduce hospital admission rates or duration of hospital stay compared with placebo. However, one RCT showed a benefit of inhaled ipratropium for children with bronchiolitis with bronchodilators in a group comparison. Also, 1 of 2 RCTs comparing dexamethasone with placebo showed a lower hospital admission rate for dexamethasone. In 1 of 2 RCTs comparing prednisolone plus placebo showed more hospital admissions with prednisolone than with placebo. One RCT showed short term improvement in clinical scores 30–60 minutes after inhaled bronchodilator therapy, and 1 RCT showed worse scores. Groups did not differ for hospitalisation when nebulised ipratropium resonance was compared with nebulised salbutamol (1 RCT) or used in combination with salbutamol or albuterol and compared with either drug alone or placebo (2 RCTs). Parenteral corticosteroids (2 RCTs [dexamethasone], 147 children). Groups did not differ for hospitalisation or clinical scores. Oral corticosteroids (5 RCTs, 273 children). 1 of 2 RCTs comparing dexamethasone with placebo showed a lower hospital admission rate for dexamethasone. 1 of 2 RCTs comparing prednisolone with placebo showed more hospital admissions with prednisolone. 1 RCT showed short term improvement in clinical scores for prednisolone plus albuterol compared with albuterol plus placebo, but the effect was not apparent at 3 or 6 days. Inhalant corticosteroids (6 RCTs, 492 children). 2 of 5 RCTs comparing budesonide with placebo or control showed longer term worsening of symptoms for budesonide (more wheezing and coughing at 12 mo and more hospital readmissions for respiratory problems at 6 mo). 1 RCT showed that 2 months of budesonide use reduced the need for asthma maintenance therapy at 2 years when compared with 7 days of budesonide use or usual symptomatic treatment. Fluticasone by metered dose inhaler (1 RCT) for 3 months led to less coughing at night in 36 weeks than did placebo, but the effect was not apparent at 3, 6, 12, or 24 weeks. Ribavirin (10 RCTs, 320 children). None of 4 placebo controlled RCTs showed a difference between groups for use of healthcare services. 1 RCT that showed improvement used sterile water as the placebo which may itself induce bronchospasm. For clinical scores (6 RCTs), 1 RCT showed that ribavirin was better than placebo for time to improvement in cough or crepitations but not for wheezing or feeding. 2 RCTs showed better clinical scores for ribavirin than for placebo on some days but not on others. 1 long term RCT showed that fewer children had ≥2 wheezing episodes at years 1–6 after ribavirin than after water placebo, but groups did not differ for overall respiratory illness or symptoms. Another RCT showed that ribavirin led to fewer episodes of reactive airways disease and upper and lower respiratory disease than did usual treatment at 1 year.

**CONCLUSION**

In children with bronchiolitis, the evidence does not consistently show that commonly used pharmacological treatments are effective.